Global Pharma Giants Invest Heavily in Chinese Biotech for Innovation and Growth

Major global pharmaceutical companies are significantly boosting their investments in China's rapidly expanding biotechnology sector. This strategic pivot is driven by the sector's substantial potential for valuation growth and its burgeoning innovation landscape, according to experts speaking at the Global Health Summit in Hong Kong.

Xu Chenming, head of the healthcare group at Hong Kong-based Citic Securities, observed that multinational pharmaceutical firms are altering their business strategies within China. "Multinational pharmaceutical companies are shifting their business strategies in China away from asset-heavy operations," Xu stated. "They are moving towards investing in companies..."

This trend signifies a move towards partnerships and investments in local Chinese biotech firms, which are increasingly recognized for their research and development capabilities. The focus is shifting from traditional manufacturing and distribution to acquiring stakes in or collaborating with companies at the forefront of drug discovery and development.

“

Multinational pharmaceutical companies are shifting their business strategies in China away from asset-heavy operations. They are moving towards investing in companies...